Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF
Open Access
- 9 July 1999
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 80 (11), 1763-1766
- https://doi.org/10.1038/sj.bjc.6690594
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Dose–response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancerEuropean Journal Of Cancer, 1998
- Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast CarcinomaNew England Journal of Medicine, 1994
- Premenopausal Patients with Node-Positive Resectable Breast CancerDrugs, 1993
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 womenThe Lancet, 1992
- Adjuvant Systemic Therapy in High-Risk Breast Cancer: The Danish Breast Cancer Cooperative Group’s Trials of Cyclophosphamide or CMF in Premenopausal and Tamoxifen in Postmenopausal PatientsPublished by Springer Nature ,1984
- Adjuvant Chemoimmunotherapy with LMF + BCG in Node-Negative and Node-Positive Breast Cancer: 8 Year ResultsPublished by Springer Nature ,1984
- A Controlled Trial of Adjuvant Chemotherapy with Melphalan Versus Cyclophosphamide, Methotrexate, and Fluorouracil for Breast CancerPublished by Springer Nature ,1984
- Combination chemotherapy for breast cancer metastatic to bone marrowCancer, 1981
- Dose-Response Effect of Adjuvant Chemotherapy in Breast CancerNew England Journal of Medicine, 1981
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958